Dublin – 2nd May 2014 - BioMarin Manufacturing Ireland, a subsidiary of BioMarin Pharmaceutical Inc. today announced that it expects to expand its Dublin operation, with the creation of up to 50 new jobs in its Dublin Global Commercial Operations Hub. BioMarin also announced this week that the European Commission approval of VIMIZIM, an enzyme replacement drug for the treatment of MPS IVA, a lysosomal storage disorder.The Dublin operation has responsibility for international supply chain, logistics and high level commercial decision making, including price, distribution and third party contracts for the launch of VIMIZIM.Read full press release here